Funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trials Proceeds will also help scale strategic partnerships with pharmaceutical and biotechnology companies Financing led by Redmile Group and Blast, with participation […]